63. 特発性血小板減少性紫斑病 Idiopathic thrombocytopenic purpura Clinical trials / Disease details

臨床試験数 : 391 / 薬物数 : 235 - (DrugBank : 50) / 標的遺伝子数 : 49 - 標的パスウェイ数 : 139

360 trials found

diseases per page:

Showing 1 to 10 of 360 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05757570 (ClinicalTrials.gov)	May 2023	24/2/2023	An Open-label Study of Povetacicept in Subjects With Autoimmune Cytopenias	A Phase 1b Open-Label Study to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics o ...	Immune Thrombocytopenia;Idiopathic Thrombocytopenic Purpura;Warm Autoimmune Hemolytic Anemia;Cold Ag ...	Drug: povetacicept	Alpine Immune Sciences, Inc.	NULL	Not yet recruiting	18 Years	N/A	All	42	Phase 1	NULL
2	NCT05653349 (ClinicalTrials.gov)	March 31, 2023	23/11/2022	Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thromb ...	A Phase III, Randomized, Double-blind Study of Ianalumab (VAY736) Versus Placebo in Addition to Firs ...	Primary Immune Thrombocytopenia (ITP)	Biological: Ianalumab;Drug: Placebo;Drug: Corticosteroids	Novartis Pharmaceuticals	NULL	Recruiting	18 Years	N/A	All	225	Phase 3	Belgium;Hungary;Romania;Singapore;Spain;United Kingdom
3	NCT05653219 (ClinicalTrials.gov)	February 2, 2023	23/11/2022	A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Imm ...	A Phase 3 Randomized, Double-blind Study of Ianalumab (VAY736) Versus Placebo in Addition to Eltromb ...	Primary Immune Thrombocytopenia	Biological: Ianalumab;Drug: Eltrombopag;Drug: Placebo	Novartis Pharmaceuticals	NULL	Recruiting	18 Years	N/A	All	150	Phase 3	Czechia;Hungary;Korea, Republic of;Singapore;United Kingdom
4	NCT05685420 (ClinicalTrials.gov)	January 23, 2023	6/1/2023	Extension Study of Herombopag for Pediatric Patients With Chronic Immune Thrombocytopenia	Extension Study of Herombopag in Children and Adolescents With Chronic Primary Immune Thrombocytopen ...	Immune Thrombocytopenia	Drug: Herombopag	Jiangsu HengRui Medicine Co., Ltd.	NULL	Not yet recruiting	6 Years	17 Years	All	117	Phase 3	NULL
5	EUCTR2022-001627-32-ES (EUCTR)	23/01/2023	01/11/2022	A phase 3, randomized, double-blind, study of ianalumab (VAY736) versus placebo in addition to eltro ...	A phase 3 randomized, double-blind study of ianalumab (VAY736) versus placebo in addition to eltromb ...	immune thrombocytopenia (ITP) MedDRA version: 23.0;Level: PT;Classification code 10083842;Term: Immu ...	Product Name: Ianalumab Product Code: VAY736 INN or Proposed INN: Ianalumab	Novartis Farmacéutica, S.A.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	150	Phase 3	United States;Philippines;Taiwan;Thailand;Spain;Italy;India;France;Malaysia;Australia;Netherlands;Ch ...
6	EUCTR2022-001627-32-NL (EUCTR)	29/12/2022	31/10/2022	A phase 3, randomized, double-blind, study of ianalumab (VAY736) versus placebo in addition to eltro ...	A phase 3 randomized, double-blind study of ianalumab (VAY736) versus placebo in addition to eltromb ...	immune thrombocytopenia (ITP) MedDRA version: 23.0;Level: PT;Classification code 10083842;Term: Immu ...	Product Name: Ianalumab Product Code: VAY736 INN or Proposed INN: Ianalumab	Novartis Pharma AG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	150	Phase 3	United States;Philippines;Taiwan;Thailand;Spain;Italy;India;France;Malaysia;Australia;Netherlands;Ch ...
7	EUCTR2022-001672-34-ES (EUCTR)	23/12/2022	11/10/2022	A study of ianalumab (VAY736) in addition to first-line corticosteroids in patients with primary imm ...	A phase III, randomized, double-blind study of ianalumab (VAY736) versus placebo in addition to firs ...	Primary Immune thrombocytopenia (ITP);Therapeutic area: Diseases [C] - Blood and lymphatic diseases ...	Product Name: Ianalumab Product Code: VAY736 INN or Proposed INN: Ianalumab	Novartis Farmacéutica, S.A.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	225	Phase 3	United States;Czechia;Hong Kong;Spain;Thailand;Turkey;Austria;United Kingdom;Italy;India;France;Czec ...
8	EUCTR2022-001627-32-CZ (EUCTR)	05/12/2022	20/10/2022	A phase 3, randomized, double-blind, study of ianalumab (VAY736) versus placebo in addition to eltro ...	A phase 3 randomized, double-blind study of ianalumab (VAY736) versus placebo in addition to eltromb ...	immune thrombocytopenia (ITP) MedDRA version: 23.0;Level: PT;Classification code 10083842;Term: Immu ...	Product Name: Ianalumab Product Code: VAY736 INN or Proposed INN: Ianalumab	Novartis Pharma AG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	150	Phase 3	Singapore;United States;Czechia;Malaysia;Thailand;Austria;Netherlands;China;Korea, Republic of;Franc ...
9	NCT05325593 (ClinicalTrials.gov)	December 2, 2022	7/3/2022	Romiplostim Plus Dexamethasone vs Dexamethasone in Patients With Newly Diagnosed Primary Immune Thro ...	A Multicentre, Randomized, Open-label Study of Romiplostim Plus Dexamethasone vs Dexamethasone in Pa ...	Primary Immune Thrombocytopenia	Drug: romiplostim plus dexamethasone;Drug: Dexamethasone	Fundación Pública Andaluza para la gestión de la Investigación en Sevilla	NULL	Recruiting	18 Years	N/A	All	126	Phase 3	Spain
10	NCT05562882 (ClinicalTrials.gov)	October 15, 2022	28/9/2022	A Clinical Trial to Assess Safety and Efficacy of Daratumumab in the Treatment of Primary Immune Thr ...	A Investigator-initiated Clinical Trial to Assess Safety and Efficacy of Daratumumab in the Treatmen ...	Immune Thrombocytopenia	Drug: Daratumumab Injection	Institute of Hematology & Blood Diseases Hospital	NULL	Not yet recruiting	18 Years	N/A	All	20	Early Phase 1	NULL

First Previous1 2 3 4 5…36Next Last